Journal
HEPATOLOGY INTERNATIONAL
Volume 12, Issue 2, Pages 83-86Publisher
SPRINGER
DOI: 10.1007/s12072-018-9855-0
Keywords
-
Categories
Funding
- La Jolla
- Novartis
Ask authors/readers for more resources
Although guidelines are available for hereditary hemochromatosis, a high percentage of the recommendations within them are not shared between the different guidelines. Our main aim is to provide an objective, simple, brief, and practical set of recommendations about therapeutic aspects of HFE hemochromatosis for p. Cys282Tyr (C282Y/C282Y) homozygous genotype, based on the published scientific studies and guidelines, in a form that is reasonably comprehensible to patients and people without medical training. This final version was approved at the Hemochromatosis International meeting on 12th May 2017 in Los Angeles.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available